Fair-Value Report — SR Medical Technology Co. Ltd. (0108.HK)

Insider Signal

Verified Snapshot

Shares outstanding cross-checked two ways: stockanalysis.com states ~3.32bn; the DI filing implies 53,000,000 / 1.6% ≈ 3.31bn. Consistent. H1 2026 interim (period end 30 Jun 2026): revenue HK$223.1m (+31% YoY), net loss HK$70.6m (swung from a marginal HK$0.9m profit in H1 2025). Financials are current — no staleness gate applies here.

Business

Legacy business: property development and investment in the UK, US and mainland China, plus PRC property management (heating supply, car-park and maintenance services) — a small, indebted, historically-loss-making HK-listed developer, ~495 staff, founded 1973.

On 5 Dec 2025 the company (then GR Life Style) agreed to acquire Beijing Chunyu Tianxia Software Co., Ltd. — operator of "Doctor Chunyu" / Chunyu Yisheng, a long-running Chinese mobile-health / tele-consultation platform (founded 2011, ~180m registered users claimed, partnerships with Tencent/Baidu/Bayer/Pfizer/GSK) — for consideration reported at roughly CNY 220–270m, ~20% payable in cash and the balance in newly issued consideration shares. Shareholders approved the share issuance at an EGM on 11 May 2026 (100% of votes cast, as expected for a related-party-driven resolution); the first cash tranche was paid in H1 2026, transferring control. The company renamed itself SR Medical Technology in July 2026 to reflect the new segment.

Chunyu Yisheng/Doctor Chunyu has raised roughly USD 240–270m over its life and, per available public reporting, has a long history of not being profitable — consistent with the broader struggle of China's consumer mHealth-app business model to monetize. The revenue growth now showing up in the group accounts is materially a consolidation effect of a loss-making asset being folded in, not evidence the segment itself has turned a corner.

Valuation

Method: asset (P/B) + scenario optionality — no FCF-DCF. This is a loss-making, story-pivot situation: a distressed/indebted legacy property book bolted onto a freshly-consolidated, historically unprofitable telehealth asset funded mostly by dilutive share issuance. A DCF would imply false precision on cash flows that don't exist yet. Fair value is anchored to book value, with scenario multiples reflecting NAV-quality risk on the overseas property book (unaudited/translated GBP, USD and CNY carrying values) against optionality on the Chunyu turnaround.

Reverse Read

At HK$1.985, the market is paying ≈3.1x book value and ≈17.4x TTM revenue (EV/Sales ≈24.9x once the HK$2.8bn net debt load is added) for a company that lost HK$182m over the trailing year and is carrying more debt than equity. That multiple only makes sense if Chunyu Yisheng turns profitable at real scale within a few years — something it has not done in 14+ years as a well-funded private company — or if there is large hidden NAV in the UK/US/PRC property book that hasn't been disclosed. Neither is supported by the current filings.

Peer Table

Median-anchored read: the two genuine, profitable, at-scale China internet-healthcare comparables trade at roughly 2x sales. SR Medical Technology — smaller, loss-making, and still majority a property company by segment history — trades at ~9x that multiple. The gap is a story-stock premium, not a fundamentals premium.

Conclusion

The insider signal is technically genuine (a real on-exchange purchase by a real, named individual, not a placing/pledge/scheme/nominee artifact) — but it is thin. A departing executive director bought a 1.6% stake at an undisclosed price and reported it over a month late, right in the middle of a name-change and story-pivot that took the shares from a 52-week low of HK$0.64 to a high of HK$4.28. That is not the profile of a high-conviction insider signal; it reads more like an incidental position from someone close to the deal than a strong buy call.

Meanwhile the price has already run far ahead of anything the balance sheet or income statement supports: ~3x book, ~17x sales, net debt exceeding equity, and the newly-acquired "medical technology" asset has a long track record of losing money. Signal real, price wrong. Rating: Avoid — this is not investable at current levels; existing holders should treat rallies as an opportunity to reduce, not add.

Key Risks

• Dilution overhang: the bulk of the Chunyu Yisheng consideration was payable in newly issued shares; further issuance/lock-up expiry could add supply.
• Leverage/refinancing: HK$2.96bn total debt against HK$119m cash and HK$2.17bn equity — thin liquidity buffer for a company with negative operating income.
• NAV opacity: overseas (UK/US) property carrying values are translated and not independently verified in this report; historically a source of write-downs at similar HK-listed developers.
• Integration/monetization risk: Chunyu Yisheng has never demonstrated sustained profitability at scale; consolidating it adds revenue but has so far widened, not narrowed, the group loss.
• Story-stock volatility: a 52-week range of HK$0.64–HK$4.28 signals this trades on narrative and flow, not earnings — sharp drawdowns are a real risk from here too.
• Governance/disclosure: a 35-day-late DI filing on a director-adjacent trade is a compliance yellow flag worth monitoring.

Sources

• HKEX DI filing DA20260916E00541 (event 12 Aug 2026, filed 16 Sep 2026)
• stockanalysis.com — price, market cap, shares outstanding, balance sheet (as of 18 Sep 2026 / TTM period ended 30 Jun 2026)
• Public reporting on the GR Life Style → SR Medical Technology rename and the Beijing Chunyu Tianxia Software (Doctor Chunyu) acquisition (EGM 11 May 2026; AGM/rename ~Jun–Jul 2026)
• Public company profiles for Chunyu Yisheng / Doctor Chunyu; Alibaba Health (0241.HK) and JD Health International (6618.HK) peer data